Retinal vein occlusion treatment market

Mar 18, 2026

Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and primarily affects people over 65, making aging a key driver of disease burden and of the growing retinal vascular occlusion market. RVO is broadly classified into central retinal vein occlusion (CRVO) and branch...

Nov 10, 2023

Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...

Jul 22, 2022

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Nov 27, 2020

Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a significant amount of other ocular complications. Any kind of blockage in the vein of the eye that carries blood from the reti...